Just when you thought it was safe to get back in the water.
The withdrawal of Biogen Idec Inc. and Elan Corp. PLC 's natalizumab (Tysabri) multiple sclerosis treatment showed that specialist products aren't immune from serious safety issues. Sales and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?